Recent Company News

• 02:50 AM ET Nov 03, 2025
  

  StreetAccount Summary - European pre-market trading update

• 01:02 AM ET Nov 03, 2025
  

  Genentech's Gazyva announces Phase III ALLEGORY study of of Gazyva (obinutuzumab) met its primary endpoint (CHF 258.90, 0.00)

• 02:13 AM ET Oct 30, 2025
  

  Roche's Bluefin Merger Subsidiary acquires all outstanding shares in 89bio ($14.84, 0.00)

• 01:12 PM ET Oct 29, 2025
  

  HHS issues press release on accelerating biosimilar drug development and lowering drug prices

• 09:21 AM ET Oct 29, 2025
  

  FDA announces draft guidance for biosimilar development

• 08:04 AM ET Oct 29, 2025
  

  Recursion Pharmaceuticals discloses Roche exercises option for Microglia Map - 8-K ($5.91, 0.00)

• 02:02 AM ET Oct 29, 2025
  

  Roche Holding receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue (CHF 261.10, 0.00)

• 05:16 PM ET Oct 28, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:48 AM ET Oct 28, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 02:05 AM ET Oct 28, 2025
  

  Roche's Genentech announces Phase III INShore study of Gazyva (obinutuzumab) met its primary endpoint (CHF 267.40, 0.00)